Id: acc2189
Group: 2sens
Protein: JAK-1
Gene Symbol: JAK1
Protein Id: P23458
Protein Name: JAK1_HUMAN
PTM: phosphorylation
Site: Tyr1023
Site Sequence: EHQVKIGDFGLTKAIETDKEY
Disease Category: Cancer
Disease: Oral Cancer
Disease Subtype: SCC
Disease Cellline: HSC-3
Disease Info:
Drug: EGCG
Drug Info: "EGCG (Epigallocatechin gallate) is a polyphenolic compound primarily found in green tea, recognized for its potent antioxidant and anti-inflammatory properties, and approved by the FDA as the main ingredient in the prescription drug Veregen? (sinecatechins) for topical treatment of genital warts caused by human papillomavirus. "
Effect: modulate
Effect Info: "EGCG blocks the IFNgamma-induced JAK-PKC-delta-STAT1 signaling pathway, inhibits IDO expression, and reduces IDO-mediated tumor immune escape."
Note:
Score: 4.0
Pubmed(PMID): 19928918
Sentence Index:
Sentence:

Sequence & Structure:

MQYLNIKEDCNAMAFCAKMRSSKKTEVNLEAPEPGVEVIFYLSDREPLRLGSGEYTAEELCIRAAQACRISPLCHNLFALYDENTKLWYAPNRTITVDDKMSLRLHYRMRFYFTNWHGTNDNEQSVWRHSPKKQKNGYEKKKIPDATPLLDASSLEYLFAQGQYDLVKCLAPIRDPKTEQDGHDIENECLGMAVLAISHYAMMKKMQLPELPKDISYKRYIPETLNKSIRQRNLLTRMRINNVFKDFLKEFNNKTICDSSVSTHDLKVKYLATLETLTKHYGAEIFETSMLLISSENEMNWFHSNDGGNVLYYEVMVTGNLGIQWRHKPNVVSVEKEKNKLKRKKLENKHKKDEEKNKIREEWNNFSYFPEITHIVIKESVVSINKQDNKKMELKLSSHEEALSFVSLVDGYFRLTADAHHYLCTDVAPPLIVHNIQNGCHGPICTEYAINKLRQEGSEEGMYVLRWSCTDFDNILMTVTCFEKSEQVQGAQKQFKNFQIEVQKGRYSLHGSDRSFPSLGDLMSHLKKQILRTDNISFMLKRCCQPKPREISNLLVATKKAQEWQPVYPMSQLSFDRILKKDLVQGEHLGRGTRTHIYSGTLMDYKDDEGTSEEKKIKVILKVLDPSHRDISLAFFEAASMMRQVSHKHIVYLYGVCVRDVENIMVEEFVEGGPLDLFMHRKSDVLTTPWKFKVAKQLASALSYLEDKDLVHGNVCTKNLLLAREGIDSECGPFIKLSDPGIPITVLSRQECIERIPWIAPECVEDSKNLSVAADKWSFGTTLWEICYNGEIPLKDKTLIEKERFYESRCRPVTPSCKELADLMTRCMNYDPNQRPFFRAIMRDINKLEEQNPDIVSEKKPATEVDPTHFEKRFLKRIRDLGEGHFGKVELCRYDPEGDNTGEQVAVKSLKPESGGNHIADLKKEIEILRNLYHENIVKYKGICTEDGGNGIKLIMEFLPSGSLKEYLPKNKNKINLKQQLKYAVQICKGMDYLGSRQYVHRDLAARNVLVESEHQVKIGDFGLTKAIETDKEYYTVKDDRDSPVFWYAPECLMQSKFYIASDVWSFGVTLHELLTYCDSDSSPMALFLKMIGPTHGQMTVTRLVNTLKEGKRLPCPPNCPDEVYQLMRKCWEFQPSNRTSFQNLIEGFEALLK

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
JAK1 ABROCITINIB Tyrosine-protein kinase JAK1 inhibitor 4 - atopic eczema FDA
EMA
JAK1 ABROCITINIB Tyrosine-protein kinase JAK1 inhibitor 4 Recruiting atopic eczema ClinicalTrials
JAK1 FILGOTINIB Tyrosine-protein kinase JAK1 inhibitor 4 - immune system disease ATC
JAK1 BARICITINIB Tyrosine-protein kinase JAK1 inhibitor 4 - immune system disease ATC
JAK1 RUXOLITINIB Tyrosine-protein kinase JAK1 inhibitor 4 - neoplasm ATC
JAK1 TOFACITINIB CITRATE Janus Kinase (JAK) inhibitor 4 Recruiting rheumatoid arthritis ClinicalTrials
JAK1 TOFACITINIB CITRATE Janus Kinase (JAK) inhibitor 4 - rheumatoid arthritis DailyMed
DailyMed
JAK1 BARICITINIB Tyrosine-protein kinase JAK1 inhibitor 4 - rheumatoid arthritis EMA
DailyMed
FDA
JAK1 BARICITINIB Tyrosine-protein kinase JAK1 inhibitor 4 Active, not recruiting rheumatoid arthritis ClinicalTrials
JAK1 BARICITINIB Tyrosine-protein kinase JAK1 inhibitor 4 Completed rheumatoid arthritis ClinicalTrials
JAK1 BARICITINIB Tyrosine-protein kinase JAK1 inhibitor 4 Recruiting rheumatoid arthritis ClinicalTrials
ClinicalTrials
ClinicalTrials
JAK1 BARICITINIB Tyrosine-protein kinase JAK1 inhibitor 4 Terminated rheumatoid arthritis ClinicalTrials
JAK1 FILGOTINIB MALEATE Tyrosine-protein kinase JAK1 inhibitor 4 - rheumatoid arthritis EMA
JAK1 UPADACITINIB HEMIHYDRATE Tyrosine-protein kinase JAK1 inhibitor 4 - rheumatoid arthritis DailyMed
FDA
JAK1 RUXOLITINIB PHOSPHATE Tyrosine-protein kinase JAK1 inhibitor 4 - polycythemia vera EMA
DailyMed
JAK1 RUXOLITINIB PHOSPHATE Tyrosine-protein kinase JAK1 inhibitor 4 - primary myelofibrosis DailyMed
JAK1 TOFACITINIB CITRATE Janus Kinase (JAK) inhibitor 4 - psoriatic arthritis DailyMed
JAK1 RUXOLITINIB PHOSPHATE Tyrosine-protein kinase JAK1 inhibitor 4 - myeloproliferative disorder EMA
JAK1 RUXOLITINIB Tyrosine-protein kinase JAK1 inhibitor 4 - Eczematoid dermatitis ATC
JAK1 ABROCITINIB Tyrosine-protein kinase JAK1 inhibitor 4 - Eczematoid dermatitis ATC
JAK1 RUXOLITINIB PHOSPHATE Tyrosine-protein kinase JAK1 inhibitor 4 - Myelofibrosis DailyMed
JAK1 RUXOLITINIB PHOSPHATE Tyrosine-protein kinase JAK1 inhibitor 4 - graft versus host disease EMA
JAK1 RUXOLITINIB Tyrosine-protein kinase JAK1 inhibitor 3 Active, not recruiting atopic eczema ClinicalTrials
JAK1 RUXOLITINIB Tyrosine-protein kinase JAK1 inhibitor 3 Recruiting atopic eczema ClinicalTrials
JAK1 BARICITINIB Tyrosine-protein kinase JAK1 inhibitor 3 Active, not recruiting atopic eczema ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - P Myeloma Phosphorylation 11986233
- - P Colon cancer/carcinoma Phosphorylation 24050550
- - U Non-small cell lung cancer/carcinoma Phosphorylation 21861134

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: